PROLASTIN-C is a concentrated form of alpha1-antitrypsin (AAT) that is purified from human plasma—the fluid part of your blood.2
When given as prescribed, PROLASTIN-C raises the levels of AAT in your blood and lungs. Because PROLASTIN® "augments" or replaces missing AAT, it is referred to as "augmentation therapy" or "replacement therapy."
It is important to know that PROLASTIN-C is not a cure for Alpha-1. PROLASTIN-C has been demonstrated to raise the plasma level of Alpha1-PI, but the effect of this augmentation on pulmonary exacerbations and on the rate of progression of emphysema has not been demonstrated in adequately powered, randomized, controlled clinical trials for any Alpha1-PI product.
Since its introduction in 1988, PROLASTIN® has been the leading augmentation therapy in the United States1 for people with Alpha-1.
The infusion time for PROLASTIN-C is approximately 15 minutes when given at the recommended rate. Because PROLASTIN-C is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.
The most common drug-related adverse reaction observed at a rate of >5% in subjects receiving PROLASTIN-C was upper respiratory tract infection. The most serious adverse reaction observed during clinical trials with PROLASTIN-C was an abdominal and extremity rash in 1 subject.
Learn more about the benefits of treating Alpha-1 with PROLASTIN-C.
PROLASTIN DIRECT® PATIENT SERVICES
One-stop PROLASTIN-C enrollment, delivery and support.
Prolastin Direct® Patient Services secures insurance authorization, coordinates infusion services, ships PROLASTIN-C directly to the location of your choice, and connects you to health management coordinators who are experienced Alpha-1 patients themselves. Find out more about Prolastin Direct® Patient Services now.